Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kevin Kelly

Showing results (111-120 of 253) with videos related to

Pageof 26
Sort By:
Biofouling|February 25, 2025
Carbon dioxide infusion reduces invasive mussel biofouling (quagga mussel; <i>Dreissena rostriformis bugensis</i>) in raw water systemsMatthew T Barbour, Todd J Severson, Jeremy K Wise, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 22, 2005
Prognostic significance of baseline reverse transcriptase-PCR for prostate-specific antigen in men with hormone-refractory prostate cancer treated with chemotherapyRobert W Ross, Judith Manola, Kristen Hennessy, et al.
Urology|July 13, 2004
Five-year outcomes after neoadjuvant chemotherapy and conformal radiotherapy in patients with high-risk localized prostate cancerCharles J Ryan, Michael J Zelefsky, Glenn Heller, et al.
Cancers|September 13, 2025
The Safety of Abiraterone Acetate in Patients with Metastatic Castration-Resistant Prostate Cancer: An Individual-Participant Data Meta-Analysis Based on 14 Randomized Clinical TrialsAmy L Shaver, Nikita Nikita, Swapnil Sharma, et al.
Urologic Oncology|June 21, 2021
New and topics: enfortumab vedotin mechanisms of response and resistance in urothelial cancer - What do we understand so far?Jean Hoffman-Censits, Kara Lombardo, David McConkey, et al.
Pharmacotherapy|May 31, 2014
A phase I study in patients with solid or hematologic malignancies of the dose proportionality of subcutaneous Azacitidine and its pharmacokinetics in patients with severe renal impairmentEric Laille, Sanjay Goel, Alain C Mita, et al.
Cancer|December 12, 2003
A phase II study of estramustine, docetaxel, and carboplatin with granulocyte-colony-stimulating factor support in patients with hormone-refractory prostate carcinoma: Cancer and Leukemia Group B 99813William K Oh, Susan Halabi, W Kevin Kelly, et al.
Journal of Geriatric Oncology|February 4, 2014
An evaluation of elderly patients (≥70 years old) enrolled in Phase I clinical trials at University of Texas Health Science Center at San Antonio-Cancer Therapy Research Center from 2009 to 2011Julie Rowe, Sukeshi Patel, Marcela Mazo-Canola, et al.
Methods in Enzymology|February 21, 2004
Histone deacetylase inhibitors: assays to assess effectiveness in vitro and in vivoVictoria M Richon, Xianbo Zhou, J Paul Secrist, et al.
Clinical Prostate Cancer|October 4, 2005
Second-line chemotherapy for prostate cancer: patient characteristics and survivalKathleen W Beekman, Mark T Fleming, Howard I Scher, et al.
Pageof 26

Showing results (111-120 of 253) with videos related to

Sort By:
Pageof 26
Biofouling|February 25, 2025
Carbon dioxide infusion reduces invasive mussel biofouling (quagga mussel; <i>Dreissena rostriformis bugensis</i>) in raw water systemsMatthew T Barbour, Todd J Severson, Jeremy K Wise, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 22, 2005
Prognostic significance of baseline reverse transcriptase-PCR for prostate-specific antigen in men with hormone-refractory prostate cancer treated with chemotherapyRobert W Ross, Judith Manola, Kristen Hennessy, et al.
Urology|July 13, 2004
Five-year outcomes after neoadjuvant chemotherapy and conformal radiotherapy in patients with high-risk localized prostate cancerCharles J Ryan, Michael J Zelefsky, Glenn Heller, et al.
Cancers|September 13, 2025
The Safety of Abiraterone Acetate in Patients with Metastatic Castration-Resistant Prostate Cancer: An Individual-Participant Data Meta-Analysis Based on 14 Randomized Clinical TrialsAmy L Shaver, Nikita Nikita, Swapnil Sharma, et al.
Urologic Oncology|June 21, 2021
New and topics: enfortumab vedotin mechanisms of response and resistance in urothelial cancer - What do we understand so far?Jean Hoffman-Censits, Kara Lombardo, David McConkey, et al.
Pharmacotherapy|May 31, 2014
A phase I study in patients with solid or hematologic malignancies of the dose proportionality of subcutaneous Azacitidine and its pharmacokinetics in patients with severe renal impairmentEric Laille, Sanjay Goel, Alain C Mita, et al.
Cancer|December 12, 2003
A phase II study of estramustine, docetaxel, and carboplatin with granulocyte-colony-stimulating factor support in patients with hormone-refractory prostate carcinoma: Cancer and Leukemia Group B 99813William K Oh, Susan Halabi, W Kevin Kelly, et al.
Journal of Geriatric Oncology|February 4, 2014
An evaluation of elderly patients (≥70 years old) enrolled in Phase I clinical trials at University of Texas Health Science Center at San Antonio-Cancer Therapy Research Center from 2009 to 2011Julie Rowe, Sukeshi Patel, Marcela Mazo-Canola, et al.
Methods in Enzymology|February 21, 2004
Histone deacetylase inhibitors: assays to assess effectiveness in vitro and in vivoVictoria M Richon, Xianbo Zhou, J Paul Secrist, et al.
Clinical Prostate Cancer|October 4, 2005
Second-line chemotherapy for prostate cancer: patient characteristics and survivalKathleen W Beekman, Mark T Fleming, Howard I Scher, et al.
Pageof 26